DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 77 filers reported holding DYNE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,924,293 | +51.4% | 54,528 | +21.8% | 0.00% | +50.0% |
| Q1 2024 | $1,271,418 | +177.4% | 44,784 | +29.9% | 0.00% | +100.0% |
| Q4 2023 | $458,411 | +45.5% | 34,467 | -1.9% | 0.00% | – |
| Q3 2023 | $314,962 | -29.6% | 35,152 | -11.6% | 0.00% | -100.0% |
| Q2 2023 | $447,548 | +12.0% | 39,782 | +14.7% | 0.00% | 0.0% |
| Q1 2023 | $399,444 | -1.9% | 34,674 | -1.3% | 0.00% | 0.0% |
| Q4 2022 | $407,029 | -7.7% | 35,119 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $441,000 | +82.2% | 34,727 | -1.3% | 0.00% | – |
| Q2 2022 | $242,000 | -22.7% | 35,190 | +8.3% | 0.00% | – |
| Q1 2022 | $313,000 | -26.2% | 32,479 | -8.9% | 0.00% | – |
| Q4 2021 | $424,000 | -25.7% | 35,648 | +1.3% | 0.00% | -100.0% |
| Q3 2021 | $571,000 | -34.4% | 35,183 | -15.0% | 0.00% | 0.0% |
| Q2 2021 | $871,000 | +131.0% | 41,411 | +70.4% | 0.00% | – |
| Q1 2021 | $377,000 | -16.6% | 24,300 | +12.9% | 0.00% | -100.0% |
| Q4 2020 | $452,000 | – | 21,524 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
| Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
| Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
| GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
| Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
| Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
| COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
| RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |